Abstract
Maternal vaccination, or vaccination in pregnancy, offers a critical opportunity to provide protection to pregnant women and simultaneously confer passive immunity to infants in the first months of life, when infections are particularly serious and their immune systems are still developing. Respiratory syncytial virus (RSV) is one such serious infectious disease for newborns, but a newly approved and recommended vaccine for respiratory syncytial virus has been designed to be given to pregnant women to protect their newborns from severe RSV disease when they are most vulnerable. While maternal vaccination has been used for tetanus, pertussis, influenza, COVID-19, and other diseases, vaccination in pregnancy can present unique challenges related to hesitancy and delivery, particularly in lower-resourced settings. Using data from a cross-sectional survey of 400 pregnant and lactating women in Nakuru and Mombasa Counties in Kenya, we examined knowledge, attitudes, and beliefs related to maternal vaccination and RSV through a latent class analysis. We identified two distinct archetypes among study subjects, maternal vaccine questioners and maternal vaccine acceptors, with notable differences in perceived vaccination-enabling social norms and use of private health facilities between the two groups. This respondent-driven approach to identify groups that may require different communication strategies can help to shape efforts to target preparations for future RSV vaccine introduction in Kenya and inform tailored health promotion strategies to support informed, confident maternal vaccination decision-making among providers, communities, and pregnant women.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported, in whole or in part, by a grant from the Bill & Melinda Gates Foundation [INV-016977] to R. Limaye/R. Karron. The conclusions and opinions expressed in this work are those of the author(s) alone and shall not be attributed to the Foundation. Under the grant conditions of the Foundation, a Creative Commons Attribution 4.0 License has already been assigned to the Author Accepted Manuscript version that might arise from this submission. Please note works submitted as a preprint have not undergone a peer review process.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was obtained from the Johns Hopkins Bloomberg School of Public Health Institutional Review Board, Baltimore, Maryland, USA (Protocol No. 14893) and the Kenya Medical Research Institute Scientific and Ethics Review Unit, Nairobi, Kenya (Protocol No. 4211), as well as the Kenya National Commission for Science, Technology and Innovation.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.